American Airlines Group Inc vs ADMA Biologics Inc — how do they compare? American Airlines Group Inc trades at $15.34 (market cap $10.55B), while ADMA Biologics Inc trades at $9.81 (market cap $2.18B). The key difference: American Airlines Group Inc is far larger — about 4.8× ADMA Biologics Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| AAL | ADMA | |
|---|---|---|
Market Cap | $10.55B | $2.18B |
Sector | Industrials | Health |
52-Week High | $18.15 | $20.38 |
52-Week Low | $10.18 | $7.60 |
Enterprise Value | $38.51B | $2.25B |
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.94, down 0.56% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is steady, reaching $54.63 billion in 2025, though net income margins are thin at 0.2%. Debt-to-asset ratios have improved to 47.25% in 2025, but negative shareholder equity remains a concern. Recent news highlights advancements in sustainable aviation fuel and premium revenue growth.
The outlook is cautiously optimistic, supported by analyst consensus favoring buy ratings (44.74%) and a $19.63 price target, implying 23% upside. Key opportunities include robust premium demand and cost management, while risks involve fuel cost volatility, high debt, and competitive pressures. Earnings execution and fuel price trends will be critical for sustained stock performance.
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Trailing returns across standard periods
Latest headlines on both assets
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →